|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1980-2-28
|
|
pubmed:abstractText |
1 The nine infants participating in this study were born to mothers who received continuous therapy with alpha-methyldopa (0.75-2.0 g/day) for several weeks extending to the time of delivery. 2 The concentration of free and total (free plus conjugated) alpha-methyldopa was determined by gas chromatography-mass spectrometry in amniotic fluid, umbilical cord plasma and maternal plasma at delivery; also in urine collected over time intervals from neonates during the first days after birth. 3 The results indicate that alpha-methyldopa administered to the mother is present in the infant at birth at a level comparable to the maternal level and persists for some days. The ratio of conjugated to free drug increases with time after birth. 4 The excretion of free and conjugated alpha-methyldopa in the urine indicated that the drug is slowly eliminated in the neonate by excretion in the urine and apparently by metabolism, mainly to the sulphate conjugate. 5 The concentration of free and conjugated alpha-methyldopa in amniotic fluid tended to be higher than in umbilical cord plasma but lower than in neonatal urine, conjugated drug predominated.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-1017153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-1034277,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-1091800,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-14102016,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-14163994,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-329859,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-4174507,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-417666,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-4646774,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-5029323,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-5029324,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-5032679,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-5948099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-596928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-5969361,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-728288,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-781212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/508547-908178
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0306-5251
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
433-40
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:508547-Amniotic Fluid,
pubmed-meshheading:508547-Female,
pubmed-meshheading:508547-Fetal Blood,
pubmed-meshheading:508547-Humans,
pubmed-meshheading:508547-Hypertension,
pubmed-meshheading:508547-Infant, Newborn,
pubmed-meshheading:508547-Male,
pubmed-meshheading:508547-Methyldopa,
pubmed-meshheading:508547-Pregnancy,
pubmed-meshheading:508547-Pregnancy Complications, Cardiovascular,
pubmed-meshheading:508547-Time Factors
|
|
pubmed:year |
1979
|
|
pubmed:articleTitle |
A study of the disposition of alpha-methyldopa in newborn infants following its administration to the mother for the treatment of hypertension during pregnancy.
|
|
pubmed:publicationType |
Journal Article
|
